Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588686 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
A Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), sponsored by Vicore Pharma AB.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT06588686 is a Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF) that is actively recruiting participants, run by Vicore Pharma AB. The registered enrollment target is 360 participants, below the 452-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (20% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06588686, a Phase 2 study of Idiopathic Pulmonary Fibrosis (IPF), is actively recruiting participants, sponsored by Vicore Pharma AB.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Buloxibutid
Study Locations (20)
California
- Keck Medicine of University of Southern California - Los Angeles
- Paradigm Clinical Research Centers, Inc. - Redding
- UC Davis Health System - Sacramento
- UC San Diego Medical Center - Hillcrest - San Diego
- Paradigm Clinical Research - San Diego
Florida
- University of Florida Health (UF Health) - Gainesville
- Clinical Research Specialists - Kissimmee
Alabama
- UAB Hospital, School of Medicine/Lung Health Center - Birmingham
Colorado
- National Jewish Medical and Research Center - Denver
Georgia
- Emory Saint Joseph's Hospital - Atlanta
Illinois
- Endeavor Health - Evanston Hospital - Evanston
Kansas
- University of Kansas Medical Center - Kansas City
Massachusetts
- Massachusetts General Hospital, Pulmonary & Critical Care Medicine - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2024-12-09 |
| Est. Completion | 2027-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06588686
The ClinicalTrials.gov registry entry for NCT06588686 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 452-participant average among 8 other Idiopathic Pulmonary Fibrosis (IPF) trials with a reported enrollment target (20% lower). The listed sponsor is Vicore Pharma AB, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis (IPF) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06588686 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06588686 about?
NCT06588686 is a clinical study titled "A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.". The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial w...
What is the current status of trial NCT06588686?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 360 participants. The study started on 2024-12-09. Estimated completion is 2027-06.
What conditions does trial NCT06588686 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis (IPF).
What interventions are being tested in trial NCT06588686?
The interventions under investigation include: Placebo (DRUG), Buloxibutid (DRUG).
Who is sponsoring clinical trial NCT06588686?
This trial is sponsored by Vicore Pharma AB, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588686 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis (IPF)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
RECRUITING · Phase 2
-
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
COMPLETED · Phase 2
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
The Genetics of Pulmonary Fibrosis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.